A new approach to gene editing, developed by Penn State researchres, using the CRISPR/Cas9 system to bypass disease-causing mutations in a gene.
IMAGE: IURIIMOTOV/FREEPIK.COM
A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases.
The method, developed and tested in mice and human tissue cultures by researchers at Penn State, involves inserting a new, fully functional copy of the gene that displaces the mutated gene.
A proof-of-concept for this approach, developed by researchers at Penn State, is described in a paper appearing Apr. 20 in the journal Molecular Therapy.
The CRISPR/Cas9 system has allowed promising new gene therapies that can target and correct disease-causing mutations in a gene. In this process, Cas9 — a bacterial protein — cuts DNA at a specific location, where the genetic sequence can then be edited, trimmed, or a new sequence inserted before the DNA is repaired. However, there are two main limitations to current repair strategies. First, the common repair strategy, called “homology-directed repair,” requires using specific proteins within the cell that are only present during cell division, which means the gene repair process cannot be used in most adult tissues where cell division occurs rarely.
“The second challenge stems from the fact that even when a disease is caused by a single gene, it can result from a variety of different mutations within that gene,” said Douglas Cavener, professor of biology at Penn State and senior author of the paper. “With homology-directed repair, we’d need to design and test the strategy for each and every one of those mutations, which can be expensive and time-intensive. In this study, we designed an approach called Co-opting Regulation Bypass Repair (CRBR), which can be used in both dividing and non-dividing cells/tissues and for a spectrum of mutations within a gene. This approach is especially promising for rare genetic diseases caused by a single gene, where limited time and resources typically preclude design and testing for the many possible disease-causing mutations.”
CRBR takes advantage of the CRISPR/Cas9 system and a cellular repair pathway called “non-homologous end joining” to insert a genetic sequence between a mutated gene’s promoter region — the genetic sequence that controls when and where the gene is functional — and the mutated portion of the gene. The newly inserted sequence contains a condensed version of the normal gene that is used in place of the mutated version. A terminator sequence at the end of the inserted sequence prevents the remaining downstream mutated gene from being used. Because CRBR does not rely on the proteins required by homology-directed repair, it can be used in all types of adult tissues.
“Our approach co-opts the native promoter for a gene,” said Jingjie Hu, a graduate student at Penn State and first author of the paper. “This means that the newly inserted gene will be expressed at the same times and at appropriate levels within the cell as the gene it is replacing. This is an advantage to other types of gene therapies, which rely on an external promoter to drive high levels of expression of the gene that could lead to negative effects if too much is produced or if essential regulation response is missing under certain physiological conditions.”
The research team conducted a series of proof-of-concept experiments to demonstrate the utility of this method. They first focused on the PERK gene, mutations in which can lead to a rare disease called Wolcott-Rallison syndrome. The syndrome results when copies of the gene inherited from both parents have mutations — it is a “recessive” disease — and can cause neonatal diabetes, skeletal problems, growth delay, and other symptoms.
The researchers inserted the PERK gene in healthy mice using CRBR and bred them with mice that had a mutation in the gene. The resulting mice, which contained one CRBR-edited PERK gene and one mutated PERK gene, did not have the typical abnormalities associated with the syndrome, indicating that the CRBR-edited gene can rescue PERK gene function in a mouse model of the Wolcott-Rallison syndrome.
Next, the researchers tested the CRBR method in human tissues, in this case focusing on the insulin gene. They inserted a green fluorescent protein marker gene sequence between the insulin gene promoter and the insulin coding sequence in human cadaver cells. This experiment resulted in the expression of the fluorescent protein in the insulin secreting cells, but not other cell types, which suggests the new sequence was strictly regulated under the control of insulin promoter.
“Our results demonstrated that CRBR gene repair can restore PERK gene function in mice and revealed the potential utility of CRBR for gene repair in human tissue,” said Hu.
The researchers note that gene editing with CRISPR/Cas9 can be error prone. For example, homology-directed repair based strategies could potentially produce damaging mutations in the coding sequence if repair does not happen properly. With CRBR, the researchers target the insertion within a region of the gene that does not code for protein, which should be more tolerant of these errors.
“Gene therapies such as CRBR that utilize CRISPR/Cas9 continue to face the challenge of delivery repair machinery into the cells of interest,” said Cavener. “One promising development is to isolate cells or tissues from the afflicted patient, repair a mutant gene in the laboratory, and then transplant the repaired cells or tissues back into the patient. We hope that, as researchers continue to improve delivery methods, CRBR can be utilized to treat Wolcott-Rallison syndrome as well other human genetic diseases.”
Original Article: Bypassing broken genes
More from: Pennsylvania State University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
CRISPR/Cas9
- 1,586 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by Prospera Financial Services Inc
Prospera Financial Services Inc acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) during the 1st quarter, according to its most recent 13F filing with the Securities & ...
- CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the twenty ratings firms that are currently covering the stock, ...
- CRISPR Gene Editing: An Overview
CRISPR gene editing utilizes Cas proteins, which help the body defend against viruses and are present in bacteria. For example, scientists can program the Cas9 protein to find and bind the protein to ...
- Intellia Therapeutics, Inc.: Intellia Therapeutics' Gene Editing Technology Looks Promising; FVE $85, Shares Undervalued
Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance ...
- CRISPR/Cas9 Market Size 2022| Segmentation, Opportunities, Companies Profiles, Trends & Forecasts To 2028
Market size and share analysis of the worldwide CRISPR/Cas9 Industry The CRISPR/Cas9 research report examines manufacturing processes and cost structures as well as development strategies and tactics.
Go deeper with Google Headlines on:
CRISPR/Cas9
Go deeper with Bing News on:
Co-opting Regulation Bypass Repair
- How to Dispose Off Your Old Phones, Electronics
The environmental watchdog prohibits anyone to dispose of e-waste by burning, burial, at a dump site, or in any undesignated waste container. Also, any member of the public is not allowed to abandon e ...
- Janes - News page
The US Navy completed a third live-fire development test (DT3) of the Northrop Grumman AGM-88G Advan ...
- Willem Kolff’s Artificial Organs
At the time there was no way to bypass the heart during surgery, so he set about building one of the first membrane oxygenators, a machine that pumps blood over a porous plastic membrane to ...
- Ask Hackaday: Does Your Car Need An Internet Killswitch?
Back in the good old days of carburetors and distributors, the game was all about busting door locks and hotwiring the ignition to boost a car. Technology rose up to combat this, you may remember ...
- Superior board passes stricter building codes for Sagamore with opt-outs
The Superior Board of Trustees approved stricter fire-resilient building codes, with an opt-out available for those impacted by the Marshall Fire.